SCHEMBL5418520

SCHEMBL5418520

CNc1nc(Nc2ccc(Cl)c(Cl)c2)ncc1NC(=O)N(C)CCO

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 6/20 0.49
▸ MAPT P10636 1/20 0.43
▸ STK17A Q9UEE5 2/20 0.42
▸ STK17B O94768 1/20 0.42
▸ HDAC3 O15379 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ APEX1 P27695 1/20 0.39
▸ JAK2 O60674 2/20 0.39
▸ SLC2A1 P11166 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SYK P43405 1/20 0.38
▸ ALK Q9UM73 3/20 0.38
▸ BTK Q06187 1/20 0.38
▸ MET P08581 2/20 0.38
▸ EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5422198 0.92 STK17A (0.42) LRRK2STK17ASTK17BHDAC3HDAC1
SCHEMBL5414042 0.90 STK17A (0.43) LRRK2STK17ASTK17BHDAC3HDAC1
SCHEMBL5410091 0.88 APEX1 (0.53) LRRK2STK17ASTK17BHDAC3HDAC1
SCHEMBL5414041 0.85 STK17A (0.44) LRRK2STK17ASTK17BHDAC3HDAC1
SCHEMBL5406186 0.83 BTK (0.50) LRRK2STK17ASTK17BHDAC3HDAC1
SCHEMBL5415948 0.82 HDAC3 (0.49) LRRK2MAPTSTK17ASTK17BHDAC3
SCHEMBL5413822 0.81 CYP3A4 (0.53) LRRK2MAPTSTK17ASTK17BHDAC3
SCHEMBL5415421 0.81 STK17A (0.48) LRRK2STK17ASTK17BHDAC3HDAC1
SCHEMBL5408198 0.81 HDAC3 (0.48) LRRK2STK17ASTK17BHDAC3HDAC1
SCHEMBL5418427 0.80 HDAC3 (0.47) LRRK2STK17ASTK17BHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 LRRK2 619/4885MAPT 13/4885STK17A 3301/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 LRRK2 775/4885MAPT 12/4885STK17A 3456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback